Search Results 181-190 of 16642 for alopecia

  1. Publications - Olayemi Sokumbi, M.D. - Mayo Clinic

    Rituximab-Induced Alopecia Universalis in a Patient With Bullous Pemphigoid. J Drugs Dermatol. 2022 Aug 1; 21 (8):894-895. View PubMed; Smith SDB, Okoye GA ...

  2. Abemaciclib Versus Placebo in Patients With Advanced Dedifferentiated Liposarcoma - Mayo Clinic

    residual alopecia or Grade 2 peripheral neuropathy prior to randomization. A washout period of at least 21 days is required between last chemotherapy dose ...

  3. Publications - Uma Thanarajasingam, M.D., Ph.D. - Mayo Clinic

    Extensive scarring alopecia and widespread rash. J Fam Pract. 2022 Mar; 71 (2):E13-E15 View PubMed; Castillo RM, Sandefur BJ, Finch AS, Richter MD ...

  4. Lichen planus - Symptoms and causes - Mayo Clinic

    Lichen planus (LIE-kun PLAY-nus) is a condition of the skin, hair, nails, mouth and genitals. On skin, lichen planus often appears as purple, itchy, flat bumps ...

  5. A Study to Evaluate Daratumumab/rHuPh20 +/- Lenalidomide as Post-ASCT Maintenance for Multiple Myeloma with Minimal Residual Disease (MRD) to Direct Therapy Duration - Mayo Clinic

    All ASCT-related toxicities must have recovered to ≤ Grade 1 (except for alopecia, fatigue and amenorrhea) prior to first randomization. Mucositis and ...

  6. A Study to Evaluate Durvalumab plus Topotecan or Lurbinectedin in Patients with Small Cell Lung Cancer - Mayo Clinic

    Exceptions: Neuropathy, fatigue, and/or alopecia may be grade 1. Known active central nervous system (CNS) metastases. NOTE: Patients with previously ...

  7. A Study of Oral LOXO-305 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma - Mayo Clinic

    or greater at the time of starting study treatment except for alopecia. - History of allogeneic or autologous stem cell transplant (SCT) or chimeric antigen

  8. A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers

    Ongoing toxic manifestations of previous treatments > Grade 2 with the exception of alopecia and neuropathy. Subjects with treated brain metastases with ...

  9. Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors - Mayo Clinic

    ... alopecia; Concurrent use of somatostatin analogs (SSTa) is allowed, provided that the patient is on a stable dose for at least two months and progressive ...

  10. Study of AG-270 in Participants With Advanced Solid Tumors or Lymphoma With MTAP Loss - Mayo Clinic

    Residual chronic toxicities of prior therapy ≤ Grade 2 (eg, peripheral neuropathy, residual alopecia) are allowed. Female subjects who are pre-menopausal ...